P. Jenner

发表

Increased Nigral Iron Content and Alterations in Other Metal Ions Occurring in Brain in Parkinson's Disease

C. Marsden, Y. Agid, D. Dexter, 1989, Journal of neurochemistry.

Complex I, Iron, and ferritin in Parkinson's disease substantia nigra

C. Marsden, J. Cooper, A. Schapira, 1994, Annals of neurology.

Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.

C D Marsden, Y Agid, C. Marsden, 1991, Brain : a journal of neurology.

BENZTROPINE INHIBITS TOXICITY OF MPTP IN MICE

A. J. Bradbury, C. Marsden, B. Costall, 1985, The Lancet.

Mitochondrial function in Parkinson's disease

C. Marsden, J. Cooper, A. Schapira, 1992 .

Decreased Ferritin Levels in Brain in Parkinson's Disease

C. Marsden, Y. Agid, M. Vidailhet, 1990, Journal of neurochemistry.

Mitochondrial function and parental sex effect in Huntington's disease

Y. Agid, J. Cooper, A. Schapira, 1990, The Lancet.

LIPID PEROXIDATION AS CAUSE OF NIGRAL CELL DEATH IN PARKINSON'S DISEASE

C. Marsden, Y. Agid, D. Dexter, 1986, The Lancet.

Co-localization of P450 enzymes in the rat substantia nigra with tyrosine hydroxylase

C. Marsden, D. Douek, R. Edwards, 1998, Neuroscience.

Treatment with a selective MAO B inhibitor prevents loss of dopamine in the nucleus accumbens of MPTP-treated common marmosets

C. Marsden, W. Gibb, M. Nomoto, 1989, Neuropharmacology.

A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra

C. Marsden, A. Lees, D. Dexter, 1989, Journal of neurochemistry.

Alpha-tocopherol levels in brain are not altered in Parkinson's disease.

C. Marsden, A. Lees, S. Daniel, 1992, Annals of neurology.

5-HYDROXYTRYPTAMINE MODULATION OF BRAIN DOPAMINE FUNCTION: IMPLICATIONS FOR THE TREATMENT OF PARKINSON'S DISEASE

M. Sheehy, P. Jenner, C. Marsden, 2006 .

MITOCHONDRIAL-FUNCTION IN PARKINSONS-DISEASE

C. Marsden, A. Schapira, J. Cooper, 1992 .

Oxidative DNA Damage in the Parkinsonian Brain: An Apparent Selective Increase in 8‐Hydroxyguanine Levels in Substantia Nigra

C D Marsden, A. Lees, N. Cairns, 1997, Journal of neurochemistry.

Basal Lipid Peroxidation in Substantia Nigra Is Increased in Parkinson's Disease

C. Marsden, Y. Agid, A. Lees, 1989, Journal of neurochemistry.

Mitochondrial Complex I Deficiency in Parkinson's Disease

C. Marsden, J. Cooper, D. Dexter, 1990, Lancet.

Anatomic and Disease Specificity of NADH CoQ1 Reductase (Complex I) Deficiency in Parkinson's Disease

C. Marsden, J. Cooper, S. Daniel, 1990, Journal of neurochemistry.

INCREASED NIGRAL IRON CONTENT IN POSTMORTEM PARKINSONIAN BRAIN

C. Marsden, Y. Agid, D. Dexter, 1987, The Lancet.

Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases

C. Marsden, J. Cooper, D. Dexter, 1998, Journal of the Neurological Sciences.

Mitochondrial DNA analysis in Parkinson's disease

A. Schapira, A. Harding, A. Schapira, 1990, Movement disorders : official journal of the Movement Disorder Society.

Lack of change in striatal DARPP-32 levels following nigrostriatal dopaminergic lesions in animals and in parkinsonian syndromes in man

C. Marsden, J. Girault, Y. Agid, 1990, Brain Research.

Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease

K. Lange, P. Jähnig, P. Jenner, 1991, Journal of neural transmission. Parkinson's disease and dementia section.

New insights into the cause of Parkinson's disease

C. Marsden, A. Schapira, P. Jenner, 1992, Neurology.

Reversal of behavioural abnormalities by fetal allografts in a novel rat model of striatonigral degeneration

C. Marsden, N. Quinn, G. Wenning, 1996, Movement disorders : official journal of the Movement Disorder Society.

Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia.

C. Marsden, D. Dexter, P. Jenner, 1993, Advances in neurology.

Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease

C. Marsden, A. Owen, S. Daniel, 2005, Journal of Neural Transmission.

α‐tocopherol levels in brain are not altered in Parkinson's disease

C. Marsden, A. Lees, S. Daniel, 1992 .

Partial reversal of increased preproenkephalin messenger ribonucleic acid (mRNA) and decreased preprotachykinin mRNA by foetal dopamine cells in unilateral 6‐Hydroxydopamine–Lesioned rat striatum parallels functional recovery

B. Zeng, P. Jenner, C. Marsden, 1996, Movement disorders : official journal of the Movement Disorder Society.

Evidence that [3H]Dopamine Is Taken Up and Released from Nondopaminergic Nerve Terminals in the Rat Substantia Nigra In Vitro

C. Marsden, P. Jenner, P. Jenner, 1985, Journal of neurochemistry.

Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease

P. Jenner, P. Jenner, 1993, Acta neurologica Scandinavica. Supplementum.

The substituted benzamides--a novel class of dopamine antagonists.

C. Marsden, P. Jenner, P. Jenner, 1979, Life sciences.

Altered 5‐HT metabolism with clonazepam, diazepam and diphenylhydantoin

C. Marsden, P. Jenner, E. Reynolds, 1975, The Journal of pharmacy and pharmacology.

Effect of metoclopramide on turnover of brain dopamine noradrenaline and 5‐hydroxytryptamine *

C. Marsden, P. Jenner, P. Jenner, 1975, The Journal of pharmacy and pharmacology.

Alterations in different populations of striatal dopamine receptors produced by 18 months continuous administration of cis- or trans-flupenthixol to rats

C. Marsden, P. Jenner, P. Jenner, 1984, Neuropharmacology.

An immunohistochemical study of the acute and long-term effects of 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine in the marmoset

C. Marsden, S. Hunt, P. Jenner, 1987, Neuroscience.

Clues to the mechanism underlying dopamine cell death in Parkinson's disease.

P. Jenner, P. Jenner, 1989, Journal of neurology, neurosurgery, and psychiatry.

Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.

C. Marsden, P. Jenner, P. Jenner, 1983, Biochemical pharmacology.

Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group.

D. Dexter, A. Schapira, P. Jenner, 1992, Annals of neurology.

Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam.

M. Hallett, C. Marsden, P. Jenner, 1977, Brain : a journal of neurology.

Chronic supranigral infusion of BDNF in normal and MPTP-treated common marmosets

C. Marsden, P. Jenner, R. Pearce, 1999, Journal of Neural Transmission.

Brain muscarinic cholinergic receptors in Huntington's disease

C. Marsden, Y. Agid, K. Lange, 1992, Journal of Neurology.

Acute dystonia induced by neuroleptic drugs

C. Marsden, P. Jenner, P. Jenner, 2004, Psychopharmacology.

Repeated levodopa infusions in fluctuating Parkinson's disease: clinical and pharmacokinetic data.

C. Marsden, F. Stocchi, P. Jenner, 1986, Clinical neuropharmacology.

Striatal dopamine receptors become supersensitive while rats are given trifluoperazine for six months

C. Marsden, P. Jenner, A. Clow, 1979, Nature.

Cation regulation differentiates specific binding of [3 H]sulpiride and [3 H]spiperone to rat striatal preparations

P. Jenner, P. Jenner, C. Marsden, 1980, The Journal of pharmacy and pharmacology.

Substituted benzamides as cerebral dopamine antagonists in rodents

C. Marsden, P. Jenner, P. Jenner, 1977, Neuropharmacology.

Comparison of the In‐vitro Receptor Selectivity of Substituted Benzamide Drugs for Brain Neurotransmitter Receptors

J. Leysen, P. Jenner, P. Jenner, 1988, The Journal of pharmacy and pharmacology.

A comparison of in vitro and in vivo dopamine receptor antagonism produced by substituted benzamide drugs

C. Marsden, P. Jenner, A. Clow, 1978, The Journal of pharmacy and pharmacology.

Metoclopramide and dopamine receptor blockade

C. Marsden, P. Jenner, P. Jenner, 1976, Neuropharmacology.

Plasma DOPA levels and growth hormone response to levodopa in parkinsomism.

P. Jenner, A. Galea-Debono, C. Marsden, 1977, Journal of neurology, neurosurgery, and psychiatry.

Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment withl-DOPA and carbidopa

P. Jenner, C. Marsden, P. Jenner, 1992, Brain Research.

Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents

C. Marsden, D. Tarsy, C. Pycock, 2004, Psychopharmacologia.

A comparison of motor behaviours in groups of rats distinguished by their climbing response to apomorphine

C. Marsden, P. Jenner, P. Jenner, 1986, British journal of pharmacology.

Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's disease.

P. Jenner, P. Richardson, H. Kase, 1997, Trends in pharmacological sciences.

Chronic Administration Does Not Alter the Pharmacokinetic Profile of l‐Dopa in the Rat

C. Marsden, P. Jenner, S. Rose, 1993, The Journal of pharmacy and pharmacology.

The dopamine D2 agonist LY 141865, but not the D1 agonist SKF 38393, reverses parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset

C. Marsden, P. Jenner, M. Nomoto, 1985, Neuroscience Letters.

Gamma-aminobutyric acid and basal ganglia outflow pathways.

C. Marsden, C. Reavill, P. Jenner, 1984, Ciba Foundation symposium.

Altered Muscarinic and Nicotinic Receptor Densities in Cortical and Subcortical Brain Regions in Parkinson's Disease

C D Marsden, P. Jenner, K W Lange, 1993, Journal of neurochemistry.

Involvement of intrinsic cholinergic and GABAergic innervation in the effect of NMDA on striatal dopamine efflux and metabolism as assessed by microdialysis studies in freely moving rats

P. Jenner, P. Jenner, S. Rose, 2001, The European journal of neuroscience.

The role of D-1 and D-2 receptors

P. Bédard, R. Horowski, P. Jenner, 1980, Nature.

Mitochondrial complex I deficiency in Parkinson's disease.

A. Schapira, P. Jenner, A. Schapira, 1989, Advances in neurology.

in vitro characterisation of dopamine receptors in the superior colliculus of the rat

C. Marsden, S. Rose, P. Jenner, 1987, Neuropharmacology.

Dopamine receptor binding sites in the rat superior colliculus

P. Jenner, C. Marsden, J. Chivers, 1984, The Journal of pharmacy and pharmacology.